Hodgkin Lymphoma News and Research

RSS

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

VisiInc and MMRGlobal announce agreement to launch MyMedicalRecords in Australia

MMRGlobal, Inc. and VisiInc PLC (VZJ) have entered into an agreement to launch MMRGlobal’s patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product. Initially, the two companies will collaborate on offering products and services jointly to the health technology market in Australia, which is currently projected to be as much as $2.4 billion this year.

2 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating complete eradication of the cancer in cell and animal studies.

25 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL.

21 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

Targeting Aurora A gene could halt rhabdoid tumor growth in children

There are no effective treatments for rhabdoid tumors - aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys. The disease is extremely rare - fewer than 10 cases are diagnosed each year in the U.S. - but is particularly difficult to treat and almost always fatal.

6 May 2011

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.

2 May 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

New findings show relation between breast implants and anaplastic large cell lymphoma

Breast implants appear to be associated with a rare form of lymphoma, but there is not yet evidence to show that the cancer is caused by implants or to suggest an underlying mechanism for how the disease might develop, according to a study by researchers from the RAND Corporation.

20 Apr 2011